Welcome to TCR-based Therapies Summit 2021
As the cancer immunotherapy space continues to mature, TCR-T therapies remain one of the most exciting frontiers in cell therapy as TCR based therapies boast enhanced target repertoires and hold the power for enhanced efficacy in solid tumor indications.
And with an ever-increasing number of TCR-T’s entering the clinic and several trials due to be read out this year, the virtual 2nd TCR-based Therapies Summit remains your one-stop shop to hear the latest clinical case studies and gain exclusive insights into the advances in fundamental TCR therapeutic development in solid tumors.
Join us virtually this June, as the trailblazers of TCR therapeutics, from the likes of Immunocore, Tscan, T-Cure Bioscience and Abbvie come together to drive the clinical development of safe and efficacious TCR therapies.
What’s New for 2021?
With the 2nd TCR-based Therapies Summit returning online this year, we’ve ensured plenty of new content to keep your agenda fresh and exciting!
Here is what is new for you this year:
TCR Biology Focus Day:
- A very popular new addition to the program, join the likes of 3T Bioscience, Seattle Children’s Research Institute, and Ziopharm Oncology at this dedicated focus day to supercharge your knowledge on optimizing binding affinity, overcome T cell exhaustion and much more!
This year gain access to exclusive talks from new companies to the TCR-based Therapies Summit including Enara Bio, Abbvie and Medigene
Join us as they discuss the discovery of novel TCR targets, overcoming the hostile tumor microenvironment, and optimizing soluble approaches to accelerate the development of next-generation TCR therapies.
2 New Pre-conference Workshops:
- Complementing the 2021 agenda, our two intimate online workshops delve deeper into the subject matter at hand, and are the perfect opportunity to learn from our world-class experts from Immunocore and Tcure Bioscience to show you how to optimize pre-clinical development, and navigate through key clinical challenges to bring TCR therapies to patients in need